An aggressive case of a thoracic undifferentiated SMARCA4-deficient tumor with extensive pleural involvement

Thorac Cancer. 2024 Apr;15(10):847-851. doi: 10.1111/1759-7714.15230. Epub 2024 Feb 23.

Abstract

SMARCA4-deficient undifferentiated thoracic tumors are a rare phenomenon. A 40-year-old male was newly diagnosed with SMARCA4-deficient undifferentiated non-small cell lung cancer. He had a history of heavy smoking and job-related exposure to metal dust and melted nickel. CT imaging showed numerous right-sided pleural masses and soft tissue plaques, but no metastases. CT-guided biopsy of a pleural mass confirmed the diagnosis. He was prescribed six cycles of carboplatin paclitaxel, and follow-up imaging showed largely stable disease. Treatment was changed to nivolumab due to shortness of breath, and he received one cycle of nivolumab without considerable side effects. Unfortunately, during the second cycle of his nivolumab, the patient presented with new weakness. Imaging showed spinal cord metastasis and he underwent a laminectomy; he was subsequently followed up as an outpatient. The objective of this publication was to explore SMARCA4-deficient undifferentiated thoracic tumors, other related SMARCA4-deficient tumors, and their overall pattern of presentation. The genetic aberrations of this case are compared to recent publications that also discuss genetic aberrations commonly occurring with this disease process, with an ultimate goal of hastening detection and adding to the library of treatment results.

Keywords: SMARCA4; SMARCA4‐deficient undifferentiated thoracic tumors; lung cancer; undifferentiated thoracic tumors.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Biomarkers, Tumor / genetics
  • Carcinoma, Non-Small-Cell Lung*
  • DNA Helicases / genetics
  • Humans
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / genetics
  • Male
  • Nivolumab
  • Nuclear Proteins / genetics
  • Sarcoma* / pathology
  • Thoracic Neoplasms* / pathology
  • Transcription Factors / genetics

Substances

  • Nivolumab
  • Biomarkers, Tumor
  • SMARCA4 protein, human
  • DNA Helicases
  • Nuclear Proteins
  • Transcription Factors